Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD‐1 inhibitor therapy for metastatic melanoma
| Autor: | Parmvir Singh, Scott P Wolfe, Silvija P. Gottesman, Allireza Alloo |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pathology
medicine.medical_specialty Histology Interstitial granulomatous dermatitis business.industry Lymphoproliferative disorders Ipilimumab Dermatology medicine.disease Morbilliform Inflammatory bowel disease Pathology and Forensic Medicine 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis medicine Sarcoidosis Nivolumab business Systemic vasculitis medicine.drug |
| Zdroj: | Journal of Cutaneous Pathology. 47:65-69 |
| ISSN: | 1600-0560 0303-6987 |
| DOI: | 10.1111/cup.13562 |
| Popis: | Checkpoint inhibition has become an important target in the management of malignant melanoma. As anti-CTLA4 inhibitors and anti-PD1 antibodies are increasingly utilized, reports of immune-related adverse events (IRAEs) are becoming more frequent. Common noted cutaneous IRAEs are morbilliform, lichenoid, bullous, granulomatous, psoriasiform, and eczematous eruptions. We report a case of interstitial granulomatous dermatitis and granulomatous arteritis in the setting of nivolumab (anti-PD1) monotherapy for metastatic melanoma. There are many different causes for granulomatous vasculitis, such as herpes virus infection, lymphoproliferative disorders, systemic vasculitis, and inflammatory bowel disease. This report adds to the growing literature on granulomatous IRAEs due to checkpoint inhibition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|